Stroke is one of the leading causes death and major functional disability worldwide. Treatment options for acute stroke are limited with many patients having residual neurologic impairment. The purpose of this study is to evaluate the safety and efficacy of elezanumab and assess change in neurologic function in participants following an acute ischemic stroke.
Elezanumab is an investigational drug being developed for the treatment of acute ischemic stroke. This 52-week study is "double-blinded', which means that neither the participants nor the study doctors will know who will be given elezanumab and who will be given placebo (does not contain treatment drug). Participants will be assigned to one of two groups, called treatment arms. Participants in one arm will receive elezanumab and participants in the other arm will receive placebo. There is a 1 in 2 chance that participants will be assigned to placebo. Approximately 120 subjects will be enrolled in 45 sites worldwide.
Participants will be randomized to elezanumab or placebo by intravenous (IV) infusion within 24 hours of "last known normal" (time when the participant was last known to be without signs and symptoms of the current stroke) and every 4 weeks thereafter for 48 weeks for a total of 13 doses.
There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of elezanumab will be checked by medical assessments, blood tests, evaluation of side effects, and completion of questionnaires.

开始日期2020-11-09

申办/合作机构

AbbVie, Inc.

NCT04295538

/ Completed临床2期

A Randomized, Double-Blind, Placebo-Controlled Proof of Concept Study to Assess the Safety and Efficacy of Elezanumab in Acute Traumatic Cervical Spinal Cord Injury

Acute Spinal Cord Injury (SCI) is a rare injury that leads to permanent neuromotor impairment and sudden disability. Approximately 25,000 people experience cervical SCI in the United States, Europe, and Japan every year. The purpose of this study is to see if elezanumab is safe and assess change in Upper Extremity Motor Score (UEMS) in participants with acute traumatic cervical SCI.
Elezanumab is an investigational drug being developed for the treatment of SCI. Elezanumab is a monoclonal antibody, that binds to an inhibitor of neuronal regeneration and neutralizes the inhibitor, thus potentially promoting neuroregeneration. This study is "double-blinded", which means that neither trial participants nor the study doctors will know who will be given which study drug. Study doctors put the participants in 1 of 2 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 3 chance that participants will be assigned to placebo. Participants 18-75 years of age with a SCI will be enrolled. Approximately 54 participants will be enrolled in the study in approximately 49 sites worldwide.
Participants will receive intravenous (IV) doses of elezanumab or placebo within 24 hours of injury and every 4 weeks thereafter through Week 48 for a total of 13 doses.
There may be a higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

开始日期2020-09-06

申办/合作机构

AbbVie, Inc.

NCT03737812

/ Completed临床2期

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis

The purpose of this study is to evaluate the safety and efficacy of elezanumab in participants with progressive Multiple Sclerosis (PMS).

开始日期2019-02-27

申办/合作机构

AbbVie, Inc.

100 项与 Elezanumab 相关的临床结果

登录后查看更多信息

100 项与 Elezanumab 相关的转化医学

登录后查看更多信息

100 项与 Elezanumab 相关的专利（医药）

登录后查看更多信息

项与 Elezanumab 相关的文献（医药）

2026-07-03·EXPERT OPINION ON INVESTIGATIONAL DRUGS

Elezanumab for the treatment of spinal cord injury: assessing the clinical development journey to date

Review

作者: Mothe, Andrea J. ; Fehlings, Michael G. ; Tator, Charles H. ; Monnier, Philippe P.

INTRODUCTION:

Traumatic spinal cord injury (SCI) is a debilitating condition with serious neurological and quality of life impact. Despite advances in surgical, medical and rehabilitative care, no approved therapies currently promote neural repair or regeneration. Repulsive Guidance Molecule a (RGMa) is a potent inhibitor of neurite growth that also regulates neuronal survival and differentiation during development. In the adult central nervous system (CNS), RGMa is expressed at low levels and rapidly upregulated in multiple cell types following SCI. RGMa-neogenin signaling induces growth cone collapse, inhibits axonal regeneration, and contributes to neuronal death and neuroinflammation, limiting recovery. Human monoclonal antibodies targeting RGMa, including elezanumab, have shown neuroprotective and neuroregenerative effects in preclinical models, supporting clinical investigation.

AREAS COVERED:

This review outlines SCI pathophysiology, RGMa upregulation after injury, key CNS signaling mechanisms, and the early development of anti-RGMa monoclonal antibodies.

EXPERT OPINION:

Two concurrent, independent clinical trials of anti-RGMa antibodies offer a unique opportunity for cross-validation and comparison across patient populations. However, these trials were recently completed, and results are not yet reported. The translation of SCI therapeutics to clinical practice is historically challenging and the controlled conditions of preclinical studies may not fully capture the complexity and variability of human SCI.

2025-10-01·International Forum of Allergy & Rhinology

Elezanumab Accelerates Post‐Injury Regeneration of Olfactory Sensory Neurons in a Methimazole‐Induced Mouse Model

Article

作者: Kobayashi, Masayoshi ; Mori, Eri ; Tanaka, Hirotaka ; Nishijima, Hironobu ; Ueha, Rumi ; Kondo, Kenji ; Otori, Nobuyoshi

Key Points:

Elezanumab accelerates olfactory sensory neuron regeneration in a methimazole‐induced mouse model.Repulsive guidance molecule A blockade increases GAP43+ and OMP+ cells dorsally while sparing basal cells.This approach offers a novel therapy for sensorineural olfactory disorder.

2024-08-01·Translational Stroke Research

Neutralizing RGMa with Elezanumab Promotes Cerebroprotection and Recovery in Rabbit Middle Cerebral Artery Occlusion

Article

作者: Weiss, Sabine ; Fung, Emma ; Smith, Elaine ; Awwad, Khader ; Zhang, Xiaomeng ; Mollon, Jennifer ; Mordashova, Yulia ; Fox, Gerard B ; Jacobson, Peer B ; Huang, Lili ; Droescher, Mathias ; Gold, Michael ; Levy, Aharon ; Ziemann, Adam ; Mothe, Andrea ; Dreher, Ingeborg ; Tator, Charles H ; Nimmrich, Volker ; Pfleeger, Kimberly ; Barghorn, Stefan ; Hooker, Bradley A ; Buck, Wayne R ; Krakovsky, Michael

Abstract:

Repulsive guidance molecule A (RGMa) is an inhibitor of neuronal growth and survival which is upregulated in the damaged central nervous system following acute spinal cord injury (SCI), traumatic brain injury, acute ischemic stroke (AIS), and other neuropathological conditions. Neutralization of RGMa is neuroprotective and promotes neuroplasticity in several preclinical models of neurodegeneration and injury including multiple sclerosis, AIS, and SCI. Given the limitations of current treatments for AIS due to narrow time windows to intervention (TTI), and restrictive patient selection criteria, there is significant unmet need for therapeutic agents that enable tissue survival and repair following acute ischemic damage for a broader population of stroke patients. In this preclinical study, we evaluated whether elezanumab, a human anti-RGMa monoclonal antibody, could improve neuromotor function and modulate neuroinflammatory cell activation following AIS with delayed intervention times up to 24 h using a rabbit embolic permanent middle cerebral artery occlusion model (pMCAO). In two replicate 28-day pMCAO studies, weekly intravenous infusions of elezanumab, over a range of doses and TTIs of 6 and 24 h after stroke, significantly improved neuromotor function in both pMCAO studies when first administered 6 h after stroke. All elezanumab treatment groups, including the 24 h TTI group, had significantly less neuroinflammation as assessed by microglial and astrocyte activation. The novel mechanism of action and potential for expanding TTI in human AIS make elezanumab distinct from current acute reperfusion therapies, and support evaluation in clinical trials of acute CNS damage to determine optimal dose and TTI in humans.Graphical AbstractA: Ramified/resting astrocytes and microglia in a normal, uninjured rabbit brain. B: Rabbit pMCAO brain illustrating lesion on right side of brain (red), surrounded by penumbra (pink) during acute phase post stroke, with minimal injury to left brain hemisphere. Penumbra characterized by activated astrocytes and microglia (region in crosshair within circle), with upregulation of free and bound RGMa. C: Elezanumab binds to both free and bound RGMa, preventing full activation of astrocytes and microglia. D: Elezanumab is efficacious in rabbit pMCAO with a 4 × larger TTI window vs. tPA (6 vs. 1.5 h, respectively). In human AIS, tPA is approved for a TTI of 3-4.5 h. Elezanumab is currently being evaluated in a clinical Ph2 study of AIS to determine the optimal dose and TTI (NCT04309474).

项与 Elezanumab 相关的新闻（医药）

2026-05-02

·神经损伤关爱先锋

2026 脊髓损伤新药爆发！除了标杆药 NVG-291，这几款新药个个改写治疗格局

得了脊髓损伤，最煎熬的是什么？是日复一日坚持康复训练，功能恢复却早早进入平台期，明明拼尽全力，却还是看着自己的运动、感觉、二便功能一步步衰退，从能扶着行走慢慢沦为卧床不起，从能自主进食到连穿衣洗漱都无法自理的无力；是全天候的神经病理性疼痛、反复发作的肌肉痉挛、难以启齿的二便失禁，一点点磨掉生活的尊严与希望的绝望；是明明按时用药、规范治疗，却只能暂时缓解症状，始终无法修复受损的脊髓神经，拦不住病情持续进展的无奈。但很多人不知道的是，脊髓损伤的新药研发从没停止。2025-2026 年，全球脊髓损伤治疗领域迎来爆发式突破，多款新药已经走到上市门口，有的能比传统药物更平稳地控制痉挛、疼痛等顽固并发症，副作用更小；有的能直击病根阻断神经继发性损伤，延缓甚至逆转功能衰退；还有的能直接唤醒神经元再生潜能、修复受损神经环路，每一款都可能给脊髓损伤患者的生活带来翻天覆地的改变。一、直击病根！这些药能真正拦住病情进展、修复受损神经传统脊髓损伤的治疗，比如急性期的脱水、激素冲击，慢性期的神经营养药、解痉止痛药，本质都是 “对症处理”—— 只能暂时减轻水肿、控制炎症、缓解不适症状，却拦不住损伤后神经元持续凋亡、轴突再生被抑制、胶质瘢痕持续增生的核心病理进程，更挡不住神经功能一步步恶化，最终导致终身残疾。而下面这些新药，均属于疾病修饰与神经修复治疗，直接冲着脊髓损伤的致病根源去，从源头阻断继发性损伤、唤醒神经元再生潜能、修复受损神经环路，甚至逆转已出现的功能障碍，这也是所有脊髓损伤患者最核心的希望。1. 瑞沙替胺：慢性脊髓损伤的 “量身定制” 靶向药这款药是由赛诺菲研发的全球首创 NgR1（Nogo 受体 1）受体反向激动剂，目前已正式向中国国家药品监督管理局和美国 FDA 提交上市申请，有望在 2026 年内获批，是目前脊髓损伤靶向治疗领域进展最快的口服新药。大白话讲就是：绝大多数脊髓损伤患者功能无法恢复，核心原因是损伤后 NgR1 这个受体 “过度激活”，它会启动下游的抑制信号通路，彻底锁住受损轴突的再生能力，同时加重局部炎症反应与胶质瘢痕增生，让神经信号无法跨损伤传导，最终导致运动、感觉等功能的永久性障碍。而瑞沙替胺能精准管住这个 “捣乱的受体”，将其反向调节至生理水平，从源头上阻断轴突再生的抑制信号，重新打通神经修复的通路，给受损神经元穿上一层 “保护罩”，从根源上放慢甚至逆转病情进展的脚步。它的获批底气来自扎实的国际多中心 III 期临床试验数据，这项名为 REGROW-SCI 的研究，共纳入 426 名病程 12-36 个月、经规范康复后功能进入平台期的慢性不完全性脊髓损伤患者。结果显示，24 周治疗后，治疗组患者下肢关键肌肌力改善率达 58.7%，轻触觉、针刺觉的感觉评分改善率达 43.2%，独立生活能力量表评分平均提升 22.4 分，能有效改善患者的转移、穿衣、二便控制等日常能力，大幅降低长期照护负担。安全性方面，仅出现轻中度一过性的头晕、胃肠道不适，无严重药物相关不良反应，远优于传统神经营养类药物。2. Thiorphan（硫代 orphan）：神经元再生重编程新药，基因治疗级里程碑突破 2025 年 10 月，国际顶级医学期刊《Nature》发布了这款新药的重磅研究成果，2026 年已快速启动国际多中心 II 期临床试验，堪称脊髓损伤再生医学领域的里程碑式突破。和上面的瑞沙替胺不同，这款药的作用更 “彻底”：成年哺乳动物的中枢神经元受损后，会永久失去再生能力，核心原因是神经元转录组呈现 “抗再生表型”，无法启动胚胎时期的再生程序。而 Thiorphan 能直接重编程受损神经元的转录组，让成年后失去再生能力的神经元，重新回归胚胎期的再生状态，从源头唤醒神经元的再生潜能，相当于从神经修复的起点就按住了脊髓损伤的进展，甚至能逆转已形成的永久性神经损伤。研究数据显示，在人类成年神经元实验中，它能让神经元突起总长度增加超 30%，最长突起长度提升 23%；在大鼠严重脊髓损伤模型中，联合神经干细胞移植后，大鼠前肢抓握成功率较对照组翻倍，皮质脊髓轴突再生量提升 60%，且再生轴突能形成功能性的突触连接，真正重建了神经传导通路。更难得的是，它的安全性表现优异，持续给药未造成神经元损伤或丢失，仅出现轻微的输注相关短期不适，完全在可控范围内。对脊髓损伤患者来说，这款药第一次证实了通过神经元转录组重编程，能安全有效地唤醒成年人类神经元的再生能力，不仅给慢性期功能停滞的患者带来了 “逆转瘫痪” 的可能性，也为后续更多脊髓损伤基因与再生疗法打开了全新的大门。3. NVG-291：皮下注射就能修复神经，全类型患者都能用这款药是全球首个靶向蛋白酪氨酸磷酸酶 σ（PTPσ）的多肽治疗药物，2023 年就获得了 FDA 快速通道资格认定，2025 年 11 月公布了惊艳的 II 期临床数据，预计 2026 年年中启动全球关键性 III 期临床试验，是目前全病程适用的神经修复核心新药。脊髓损伤的功能持续恶化，本质是两大核心难题共同作用：一是损伤后神经元持续凋亡、轴突脱髓鞘，神经传导通路彻底断裂；二是胶质瘢痕持续增生，形成物理和化学双重屏障，彻底阻断轴突再生的可能。而 NVG-291 能双管齐下破解这两大难题，它既能促进神经元存活、轴突再生和髓鞘修复，重建断裂的神经传导通路；又能打破胶质瘢痕的再生屏障，同时调节损伤局部的炎症微环境，减少促炎因子释放，真正实现从根源上修复神经、逆转疾病进程。 2025 年发布的 II 期临床数据显示，这款药的安全耐受性和安慰剂相当，副作用极小。治疗 16 周后，用药患者的神经功能损伤评分改善幅度是安慰剂组的 2.6 倍，75% 的患者自觉整体症状显著改善，67% 的患者膀胱控制能力明显提升，56% 的患者肌肉痉挛程度显著降低，不少此前无法自主完成洗漱、进食的患者，重新恢复了基础生活自理能力。最关键的是，它采用皮下注射给药，无需手术、无需鞘内输注，日常使用非常方便，而且对所有类型的脊髓损伤患者都有潜在效果 —— 不管是创伤性还是非创伤性，急性期还是慢性期，完全性还是不完全性损伤。早期患者使用，有望把神经损伤牢牢控制住，大幅减少功能丧失的程度；慢性期患者使用，有望打破长期的康复平台期，实现功能的再次改善。二、告别并发症折磨！这些新药，让症状控制更稳、生活质量更高对中晚期脊髓损伤患者来说，除了神经功能无法恢复，最磨人的还有两大痛点：一是神经病理性疼痛、肌肉痉挛、二便障碍反复发作，常规药物越用效果越差，一天里大部分时间都处在疼痛、僵直、无法自主排尿的煎熬中；二是长期吃药带来的副作用，比如嗜睡、头晕、肝肾功能损伤、药物依赖，往往是旧痛未消又添新苦。下面这几款新药，就是专门解决这些痛点的，让患者的症状控制更平稳，用药更放心，生活质量直接提升一个台阶。1. Elezanumab（ABT-555）：近十年对症 + 修复双效治疗最大突破，全病程都能用这款药是全球首个靶向排斥性引导分子 A（RGMa）的全人源单克隆抗体，也是目前脊髓损伤治疗领域最受期待的双效新药，2026 年正在开展全球多中心 III 期临床试验，中国也同步加入了试验，是近十年来脊髓损伤对症治疗领域的最大突破。传统的对症药物，比如解痉药巴氯芬、止痛药加巴喷丁，大多只能单一缓解痉挛或疼痛，不仅容易引发嗜睡、头晕、乏力、药物耐受等副作用，还对神经修复没有任何帮助，长期使用甚至会加重神经功能衰退。而 Elezanumab 精准避开了这些弊端，它既能直接抑制损伤后的炎症级联反应，快速减轻神经病理性疼痛和肌肉痉挛，又能同时促进轴突再生、改善神经传导，实现 “对症控症 + 根源修复” 的双重获益，还能把全身副作用降到最低。 2026 年最新发布的临床研究结果显示，它的疗效覆盖脊髓损伤全病程：针对慢性期患者，和常规对症治疗联用后，患者的疼痛数字评分平均降低 4.2 分，痉挛发作频率减少 68%，每天无痛、无严重痉挛的舒适时间平均增加 3.5 小时，且不会增加嗜睡、头晕等中枢抑制副作用；针对急性期患者，单药使用就能显著减轻继发性神经损伤，大幅提升运动、感觉功能的恢复程度，有效降低进展为完全性瘫痪的风险。对脊髓损伤患者来说，这款药真正实现了 “全病程获益”，急性期能单药保护神经、减少损伤，慢性期能解决顽固疼痛、痉挛等核心并发症，关键是中枢副作用、药物依赖风险远低于传统对症药物，为患者提供了更安全、更长效的治疗选择。2. 瑞奈替德（髓索宁）：急性期脊髓损伤的 “救命药”，全程平稳控损伤这款药是全新一代口服 Rho 激酶抑制剂，2026 年已由国内顶尖医学中心牵头完成中国 III 期注册临床试验，正式向国家药监局提交上市申请，引进与落地工作正在快速推进。很多急性期脊髓损伤患者，即便及时做了手术减压，后续还是会出现严重的继发性损伤 —— 水肿、炎症、缺血持续加重神经损害，最终从不完全性损伤进展为完全性瘫痪。而常规的脱水、大剂量激素冲击治疗，不仅效果有限，还容易带来消化道出血、严重感染、血糖紊乱等致命副作用，临床应用受到极大限制。而瑞奈替德就像损伤部位的 “持续稳定剂”，通过口服给药就能精准穿透血脊髓屏障，24 小时平稳抑制 Rho/ROCK 通路，持续减轻损伤部位的水肿、炎症和缺血再灌注损伤，阻断神经元的继发性凋亡，同时为轴突再生创造有利条件，彻底告别传统激素冲击带来的血药浓度忽高忽低和严重不良反应。国内 III 期临床试验数据显示，针对急性期不完全性脊髓损伤患者，瑞奈替德治疗第 4 周即可显现显著的功能改善优势，24 周治疗后，患者 ASIA 运动功能评分较安慰剂组平均提升 12.6 分，感觉评分平均提升 18.3 分，疗效随治疗周期延长持续提升，且安全性显著优于传统激素治疗方案。对于急性期创伤性脊髓损伤、术后神经功能仍在持续恶化的患者，这款药能帮他们牢牢守住残存的神经功能，大幅降低完全性瘫痪的风险，为后续的康复治疗打下坚实的基础。最后，想和所有脊髓损伤患者说：很多患者常常会问：脊髓损伤什么时候才能被攻克？其实，所谓的攻克，从来都不是某一天突然出现的一款神药，而是像我们今天说的这些新药一样，一步一个脚印：从只能暂时缓解并发症，到能从根源阻断继发性损伤，再到能直接唤醒神经元再生、修复受损神经环路，一步步靠近逆转瘫痪、治愈疾病的终点。从即将在 2026 年获批的瑞沙替胺，到快速推进 III 期试验的 NVG-291，再到领跑全球的国产 iPSC 再生神经细胞疗法，我们能清晰地看到，脊髓损伤治疗的新时代，已经来了。也许今天的这些新药，还不能马上让每一位患者都用上，但它们每一个突破性的进展，都在给我们带来更多的希望，都在把治愈的终点，拉得更近一点。温馨提示：如果您或您身边的人患有神经损伤疾病，建议及时寻求专业医师的帮助，制定科学合理的治疗方案。 “养髓复痿汤”由杜传太中医师依据中医整体观与辨证论治思想，结合数十载临床心得潜心创制而成。该方剂以益气养血、通经活络、修复神经为根本法则，精选道地名贵药材，通过严谨配伍，旨在从本源上促进神经损伤的修复与功能重建，提升患者康复水平。方中诸药相辅相成，既能补益气血以濡养经脉，又能活血通络以畅达气机，有效改善肢体麻木、无力、感觉异常及运动障碍等症状，同时调和脏腑机能，增强组织再生能力，降低后遗症风险。杜传太中医师凭借其近二十年对神经系统疾病的专注研究与大量临床实践，精心研发出此中医药方《养髓复痿汤》。这一汤剂凝结了杜医师深厚的学术积淀与丰富的治疗智慧，专为神经损伤患者而设。它直抵病所，进行系统性调理，能够有效促进受损神经的恢复，改善神经传导功能，帮助患者重获运动与感觉能力，提升生活自理质量。杜传太中医师说：“如果想采用中医治疗神经损伤疾病，进行辨证分型很重要，因为治疗都是根据患者情况进行一人一方的针对性调理治疗，具体还是需要医生给予相应的诊察，设定相应的治疗方案!可以采用的方法一般有来北京面诊和远程微信视频看诊两种方式”! 长按扫码关注神经损伤了解更多相关资讯获取更多质询，可以点击长按二维码关注，或拨打热线：15724726836

2024-11-13

·PRNewswire

75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight

Multiple sclerosis (MS) is a chronic neurological disorder affecting the central nervous system (CNS), particularly the brain, spinal cord, and optic nerves. Continuous research has led to new drug developments, particularly disease-modifying therapies (DMTs) that slow MS progression. Monoclonal antibodies, oral therapies, and infusion treatments are among the most promising options and drives the multiple sclerosis market. LAS VEGAS, Nov. 13, 2024 /PRNewswire/ -- DelveInsight's ' Multiple Sclerosis Pipeline Insight 2024 ' report provides comprehensive global coverage of pipeline multiple sclerosis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the multiple sclerosis pipeline domain. Key Takeaways from the Multiple Sclerosis Pipeline Report DelveInsight's multiple sclerosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for multiple sclerosis treatment. Key multiple sclerosis companies such as Mapi Pharma, Novartis, Immunic, Biocad, Apimeds, Genentech (Roche), AB Science, Celltrion, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, GeNeuro SA, AbbVie, BrainStorm Cell Therapeutics, NeuroSense Therapeutics, Denali Therapeutics Inc., Sanofi, MediciNova, Biogen, Tiziana Life Sciences, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Eli Lilly and Company, Axsome Therapeutics, Accure therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio-Technology Co., Ltd., ImCyse, Lucid Psycheceuticals, Immune Response BioPharma, Guangzhou Lupeng Pharmaceutical, Kyowa Kirin, Nura Bio, Bristol-Myers Squibb, ImStem Biotechnology, Hoffmann-La Roche, LAPIX Therapeutics, Motric Bio, Immunophage Biotech, NervGen, FibroBiologics, Kyverna Therapeutics, GlaxoSmithKline, PolTREG, Cyxone, Biohaven Pharmaceuticals, HuniLife Biotechnology, GlobeStar Therapeutics, Anokion, Medsenic, ZyVersa Therapeutics, Alumis Inc., Axoltis Pharma, Barricade Therapeutics, BioNxt Solutions, Eikonoklastes Therapeutics, 4D Pharma, Gossamer Bio, Pasithea Therapeutics, Synaptogenix, Monte Rosa Therapeutics, Immix Biopharma, f5 Therapeutics, Autobahn Therapeutics, Biosenic, Polpharma Biologics, Find Therapeutics, TeraImmun, AptaTargets, Trethera, Aditxt, SetPoint Medical, Sarepta Therapeutics, Nucleome Therapeutics, Vaccinex Inc., and others are evaluating new multiple sclerosis drugs to improve the treatment landscape. Promising multiple sclerosis pipeline therapies such as GA Depot, Remibrutinib, Tolebrutinib, IMU 838, BCD-132, Apitox, Fenebrutinib, SAR 441344, CT-P53, CNM-Au8, Orelabrutinib, Vafidemstat, Temelimab, Elezanumab, NurOwn (MSC-NTF cells), PrimeC, SAR4433820, Ibudilast, BIIB091, Foralumab, ATL1102, RC18, ATA188, PIPE-307, Pirtobrutinib, LY3541860, Solriamfetol, Act-01, SCM-010, UMSC01, IMCY-0141, Lucid-MS, NeuroVax, LP-168, NB-4746, CC-97540, IMS-001, RO7121932, BMS-986196, LPX-TI641, MTR-601, IPG-11406, IPG-1094, NVG-291, CYMS-101, KYV-101, PIPE-791, GSK 3888130B, PTG-007, T 20K, BHV-8000, HuL001, Amethyst™, ANK 700, Arscimed, A-005, NX210c, Research programme: CAR-TREG, TASIN-1, Cladribine ODF, ET-101, MRx0002, GB7208, PAS-002, Bryostatin-1, MRT-6160, NXC-201, Research Program: Cytokine reduction, ABX-002, Arsenic trioxide, LL-341070, PB018, FTX 101, TI-235, TRE 515, NT-0007, NT-0002, NVG300, and others are under different phases of multiple sclerosis clinical trials. In October 2024, Immunic, Inc. reported favorable results from the non-binding interim futility analysis of its Phase 3 ENSURE trial, which is evaluating its lead candidate, vidofludimus calcium (IMU-838), a nuclear receptor-related 1 (Nurr1) activator, for the treatment of relapsing multiple sclerosis (RMS). In October 2024, Immunic, Inc. announced a positive outcome of the non-binding, interim futility analysis of its Phase III ENSURE program, investigating lead asset, nuclear receptor related 1 (Nurr1) activator, vidofludimus calcium (IMU-838), for the treatment of relapsing multiple sclerosis (RMS). Based on the outcome of the interim futility analysis, an unblinded Independent Data Monitoring Committee (IDMC) has recommended that the trials are not futile and should continue as planned. In September 2024, Roche, secured FDA approval for an injectable form of its blockbuster multiple sclerosis treatment, Ocrevus, reducing patient treatment time and potentially helping the company stay ahead of increasing competition. In September 2024, Sanofi announced the outcomes of Phase III clinical trials of its investigational oral brain-penetrant BTK inhibitor, tolebrutinib, aimed at treating multiple sclerosis (MS). These studies, namely HERCULES, GEMINI 1, and GEMINI 2, have provided mixed results, with the HERCULES trial meeting its primary endpoint while the GEMINI trials did not. The HERCULES study focused on the efficacy and safety of tolebrutinib in individuals with non-relapsing secondary progressive MS (nrSPMS) compared to a placebo. In August 2024, Abata Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ABA-101 for the treatment of patients with progressive multiple sclerosis (MS). The FDA recently cleared ABA-101's Investigational New Drug (IND) application, and initiation of a first-in-human (FIH) Phase I study is imminent. In August 2024, TG Therapeutics announced that the FDA has cleared an investigational new drug (IND) application submitted by TG Therapeutics for azercabtagene zapreleucel (azer-cel), an investigational allogeneic chimeric antigen receptor T-cell (CAR-T) therapy, for a phase 1 clinical trial in patients with progressive multiple sclerosis (MS). In January 2024, Kyverna Therapeutics, Inc. announced it received fast-track designation by the U.S. Food and Drug Administration (FDA) for its autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate, KYV-101, to be used for the treatment of multiple sclerosis (MS). Request a sample and discover the recent advances in multiple sclerosis treatment drugs @ Multiple Sclerosis Pipeline Report The multiple sclerosis pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage multiple sclerosis drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the multiple sclerosis clinical trial landscape. Multiple Sclerosis Overview Multiple sclerosis is a chronic autoimmune disorder that affects the central nervous system, leading to the deterioration or permanent damage of myelin, the protective sheath surrounding nerve fibers. While the exact cause of multiple sclerosis remains unclear, it is believed to involve a combination of genetic predisposition, environmental factors, and possibly viral infections. Common symptoms of multiple sclerosis include fatigue, difficulty walking, numbness or tingling in the limbs, muscle weakness, and vision problems, which can vary significantly among individuals and may evolve over time. Diagnosis typically involves a combination of neurological examinations, magnetic resonance imaging (MRI) to detect lesions in the brain and spinal cord, and sometimes lumbar puncture to analyze cerebrospinal fluid for inflammatory markers. While there is no cure for multiple sclerosis, treatment options aim to manage symptoms, reduce the frequency and severity of relapses, and slow disease progression. This may include disease-modifying therapies (DMTs), corticosteroids for acute exacerbations, and symptomatic treatments such as physical therapy, pain management, and lifestyle modifications. Early diagnosis and a tailored treatment plan are crucial for improving the quality of life for those living with multiple sclerosis. Find out more about multiple sclerosis treatment drugs @ Drugs for Multiple Sclerosis Treatment A snapshot of the Multiple Sclerosis Pipeline Drugs mentioned in the report: Learn more about the emerging multiple sclerosis pipeline therapies @ Multiple Sclerosis Clinical Trials Multiple Sclerosis Therapeutics Assessment The multiple sclerosis pipeline report proffers an integral view of the multiple sclerosis emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration. Scope of the Multiple Sclerosis Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Therapeutics Assessment By Mechanism of Action: Immunomodulators, MHC class II gene modulators, Agammaglobulinaemia tyrosine kinase inhibitors, Dihydroorotate dehydrogenase inhibitors, Nuclear receptor subfamily 4 group A member 2 agonists, CD20 antigen inhibitors, Energy metabolism stimulants; Immunomodulators, Lysine-specific demethylase 1 inhibitors, Monoamine oxidase B inhibitors, Protein-arginine deiminase inhibitors, Immunostimulants Key Multiple Sclerosis Companies: Mapi Pharma, Novartis, Immunic, Biocad, Apimeds, Genentech (Roche), AB Science, Celltrion, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, GeNeuro SA, AbbVie, BrainStorm Cell Therapeutics, NeuroSense Therapeutics, Denali Therapeutics Inc., Sanofi, MediciNova, Biogen, Tiziana Life Sciences, Antisense Therapeutics, RemeGen, Atara Biotherapeutics, Contineum Therapeutics, Eli Lilly and Company, Axsome Therapeutics, Accure therapeutics, Stem Cell Medicine Ltd., Ever Supreme Bio-Technology Co., Ltd., ImCyse, Lucid Psycheceuticals, Immune Response BioPharma, Guangzhou Lupeng Pharmaceutical, Kyowa Kirin, Nura Bio, Bristol-Myers Squibb, ImStem Biotechnology, Hoffmann-La Roche, LAPIX Therapeutics, Motric Bio, Immunophage Biotech, NervGen, FibroBiologics, Kyverna Therapeutics, GlaxoSmithKline, PolTREG, Cyxone, Biohaven Pharmaceuticals, HuniLife Biotechnology, GlobeStar Therapeutics, Anokion, Medsenic, ZyVersa Therapeutics, Alumis Inc., Axoltis Pharma, Barricade Therapeutics, BioNxt Solutions, Eikonoklastes Therapeutics, 4D Pharma, Gossamer Bio, Pasithea Therapeutics, Synaptogenix, Monte Rosa Therapeutics, Immix Biopharma, f5 Therapeutics, Autobahn Therapeutics, Biosenic, Polpharma Biologics, Find Therapeutics, TeraImmun, AptaTargets, Trethera, Aditxt, SetPoint Medical, Sarepta Therapeutics, Nucleome Therapeutics, Vaccinex Inc., and others are evaluating new multiple sclerosis drugs to improve the treatment landscape. Key Multiple Sclerosis Pipeline Therapies:GA Depot, Remibrutinib, Tolebrutinib, IMU 838, BCD-132, Apitox, Fenebrutinib, SAR 441344, CT-P53, CNM-Au8, Orelabrutinib, Vafidemstat, Temelimab, Elezanumab, NurOwn (MSC-NTF cells), PrimeC, SAR4433820, Ibudilast, BIIB091, Foralumab, ATL1102, RC18, ATA188, PIPE-307, Pirtobrutinib, LY3541860, Solriamfetol, Act-01, SCM-010, UMSC01, IMCY-0141, Lucid-MS, NeuroVax, LP-168, NB-4746, CC-97540, IMS-001, RO7121932, BMS-986196, LPX-TI641, MTR-601, IPG-11406, IPG-1094, NVG-291, CYMS-101, KYV-101, PIPE-791, GSK 3888130B, PTG-007, T 20K, BHV-8000, HuL001, Amethyst™, ANK 700, Arscimed, A-005, NX210c, Research programme: CAR-TREG, TASIN-1, Cladribine ODF, ET-101, MRx0002, GB7208, PAS-002, Bryostatin-1, MRT-6160, NXC-201, Research Program: Cytokine reduction, ABX-002, Arsenic trioxide, LL-341070, PB018, FTX 101, TI-235, TRE 515, NT-0007, NT-0002, NVG300, and others are under different phases of multiple sclerosis clinical trials. Dive deep into rich insights for new drugs for multiple sclerosis treatment, visit @ Multiple Sclerosis Drugs Table of Contents For further information on the multiple sclerosis pipeline therapeutics, reach out @ Multiple Sclerosis Treatment Drugs Related Reports Multiple Sclerosis Market Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key multiple sclerosis companies including Immune Response BioPharma, Inc., Clene Nanomedicine, Genzyme, ImStem Biotechnology, Rho, Inc., Bristol-Myers Squibb, TG Therapeutics, Inc., Hoffmann-La Roche, Atara Biotherapeutics, Immunic AG, Celgene, Anokion SA, Sanofi, Actelion, Biogen, Supernus Pharmaceuticals, Inc., GeNeuro SA, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, RemeGen Co., Ltd., Antisense Therapeutics, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, Solstice Neurosciences, ProJenX, among others. Multiple Sclerosis Epidemiology Forecast Multiple Sclerosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted multiple sclerosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Relapsing Multiple Sclerosis Pipeline Relapsing Multiple Sclerosis Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key relapsing multiple sclerosis companies, including ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, among others. Relapsing-Remitting Multiple Sclerosis Pipeline Relapsing-Remitting Multiple Sclerosis Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key RRMS companies, including TG Therapeutics, Novartis, Sanofi, Cinnagen, Polpharma Biologics, Immunic, Mapi Pharma, Biocad, Apimeds, Genentech (Roche), Merck, Immune Response BioPharma, Clene Nanomedicine, InnoCare Pharma, Oryzon Genomics, GeNeuro SA, AbbVie, Emerald Health Pharmaceuticals, GlaxoSmithKline, RedHill Biopharma, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期临床结果快速通道细胞疗法免疫疗法

100 项与 Elezanumab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11355	-	-	DB15240

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性缺血性卒中	临床2期	美国	AbbVie, Inc.	2020-11-09
急性缺血性卒中	临床2期	日本	AbbVie, Inc.	2020-11-09
急性缺血性卒中	临床2期	澳大利亚	AbbVie, Inc.	2020-11-09
急性缺血性卒中	临床2期	加拿大	AbbVie, Inc.	2020-11-09
急性缺血性卒中	临床2期	韩国	AbbVie, Inc.	2020-11-09
急性缺血性卒中	临床2期	西班牙	AbbVie, Inc.	2020-11-09
急性脊髓损伤	临床2期	美国	AbbVie, Inc.	2020-09-06
急性脊髓损伤	临床2期	日本	AbbVie, Inc.	2020-09-06
急性脊髓损伤	临床2期	澳大利亚	AbbVie, Inc.	2020-09-06
急性脊髓损伤	临床2期	加拿大	AbbVie, Inc.	2020-09-06

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04309474 (EAISE \| Phase 2a, CTgov)	临床2期	急性缺血性卒中	121	Placebo (Placebo)	遞願網築簾顧襯襯製觸(獵衊廠網遞遞觸糧壓鬱) = 獵蓋遞製獵鹹觸築膚鹽衊範築網獵製衊壓夢醖 (窪夢淵夢製艱艱積鬱淵, 蓋廠憲鹽齋膚構窪網廠 ~ 壓觸鑰繭鏇顧齋簾憲淵) 更多	-	2025-12-22
				Elezanumab (Elezanumab)	遞願網築簾顧襯襯製觸(獵衊廠網遞遞觸糧壓鬱) = 憲齋積醖鬱遞積醖齋顧衊範築網獵製衊壓夢醖 (窪夢淵夢製艱艱積鬱淵, 繭糧壓遞觸鹽齋膚獵顧 ~ 鏇窪夢顧製糧窪壓蓋齋) 更多
NCT04309474 (Phase 2a, ISC2024)	临床2期	缺血性卒中 neurofilament light chain protein \| glial fibrillary acidic protein \| GAP43	-	Elezanumab	憲淵鹽選鑰鏇醖鹹願鹹(遞鏇獵鹹獵餘糧鹽壓願) = 簾鑰淵艱壓鏇顧衊鹽窪窪選廠壓鑰蓋構衊夢製 (繭齋觸壓衊糧壓鬱顧糧 )	积极	2024-02-01
				Placebo	憲淵鹽選鑰鏇醖鹹願鹹(遞鏇獵鹹獵餘糧鹽壓願) = 壓遞壓糧構繭顧糧網醖窪選廠壓鑰蓋構衊夢製 (繭齋觸壓衊糧壓鬱顧糧 )
NCT03737851 (RADIUS-R, CTgov)	临床2期	多发性硬化症 \| 继发进展型多发性硬化 \| 复发-缓解型多发性硬化	208	placebo (Placebo)	鏇鹹築遞繭獵簾衊鑰鹹(選廠淵觸襯獵艱範顧糧) = 衊壓壓廠繭鹹壓齋顧獵顧蓋衊衊艱憲壓憲遞製 (觸鬱製選襯蓋齋齋醖廠, 0.175) 更多	-	2023-12-22
				elezanumab (Elezanumab Dose 1)	鏇鹹築遞繭獵簾衊鑰鹹(選廠淵觸襯獵艱範顧糧) = 淵醖製憲醖遞壓憲膚鑰顧蓋衊衊艱憲壓憲遞製 (觸鬱製選襯蓋齋齋醖廠, 0.179) 更多
NCT03737812 (RADIUS-P, CTgov)	临床2期	多发性硬化症 \| 原发性进行性多发性硬化 \| 继发进展型多发性硬化	123	placebo (Placebo)	襯築繭鑰顧簾襯鹽廠顧(顧築獵齋蓋鹽鹹積簾鏇) = 糧網選鹽觸願觸鑰鑰簾鏇遞衊膚遞醖願鏇觸選 (網艱簾憲鏇鏇餘鹹簾鬱, 0.167) 更多	-	2023-12-21
				elezanumab (Elezanumab 400mg Dose)	襯築繭鑰顧簾襯鹽廠顧(顧築獵齋蓋鹽鹹積簾鏇) = 選餘網鹹願艱製網憲鹽鏇遞衊膚遞醖願鏇觸選 (網艱簾憲鏇鏇餘鹹簾鬱, 0.176) 更多
NCT02601885 (Pubmed) 人工标引	临床1期	多发性硬化症	47	Elezanumab (multiple ascending dose)	壓構願鑰餘蓋鹹繭築襯(窪蓋構鏇鬱鹽網遞鹽窪) = 獵鑰製願繭鑰繭夢鏇醖鬱築鹽鹹壓醖衊糧淵網 (夢襯積艱觸顧顧願壓鑰 ) 更多	积极	2022-09-12
NCT03737812 \| NCT03737851 (RADIUS-P, ECTRIMS2020)	临床2期	多发性硬化症	-	Elezanumab	積淵糧製簾遞鏇齋壓膚(壓醖蓋艱鬱鬱淵獵醖襯) = 艱憲襯窪鑰選醖淵構願選構鹽鬱製糧顧構鏇構 (願窪夢餘繭網築膚窪遞 )	-	2020-12-07
				Placebo	積淵糧製簾遞鏇齋壓膚(壓醖蓋艱鬱鬱淵獵醖襯) = 淵鏇艱艱願顧簾齋構築選構鹽鬱製糧顧構鏇構 (願窪夢餘繭網築膚窪遞 )
Phase 1, multiple-dose study of elezanumab (ABT-555) (ECTRIMS2018)	临床1期	复发性多发性硬化 repulsive guidance molecule A (RGMa) \| Interleukin-10	20	Elezanumab 150 mg	醖顧構製願觸糧鬱醖構(觸廠顧獵獵簾鏇窪蓋構) = 25% of all patients 艱餘廠遞艱鬱艱襯構壓 (夢鏇壓鏇膚繭築觸鏇簾 )	积极	2018-10-09
				Elezanumab 600 mg